Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Oct 18;35(2):239-247.
doi: 10.1515/jpem-2021-0458. Print 2022 Feb 23.

Non-inferiority of liquid thyroxine in comparison to tablets formulation in the treatment of children with congenital hypothyroidism

Affiliations
Randomized Controlled Trial

Non-inferiority of liquid thyroxine in comparison to tablets formulation in the treatment of children with congenital hypothyroidism

Flora Tzifi et al. J Pediatr Endocrinol Metab. .

Abstract

Objectives: The aim of the current prospective randomized control study was to assess efficacy, safety, and non-inferiority of a new liquid L-thyroxine formulation dissolved in glycerol and water (T4® drops, produced by a Greek pharmaceutical Company, Uni-Pharma, Athens, Greece) in comparison to the standard Tablets form (T4® tablets, Uni-Pharma, Athens, Greece) in the substitutive treatment of children with congenital hypothyroidism (CH).

Methods: Thirty-nine children with CH, aged 3-12 years old, were enrolled in the study, after parental Informed Consent has been obtained, while three patients were lost from follow-up. At baseline, all participants had normal thyroid-stimulating hormone (TSH) and Free T4 values. Patients were randomly subdivided according to the assigned treatment in Group A (n=17)-Tablet Form and Group B (n=19)-Liquid Form. TSH and Free T4 levels were evaluated at 0, 2, 4, and 6 months.

Results: TSH values showed a statistically significant difference (p=0.017) between groups only at six months (Group A having higher TSH levels than Group B, albeit within the normal range), while Free T4 levels had no statistical difference throughout the six month study period and were always within the normal range. Moreover, dose adjustments were more frequent in Group A (p=0.038) during the six months. Liquid L-thyroxine substitutive treatment exhibited no statistically significant adverse effects in comparison to the widely used tablets.

Conclusions: Levothyroxine (LT4) as liquid solution formulation is safe and noninferior to the widely used L-thyroxine Tablets, with less need for dose adjustment, and can therefore be safely used in the treatment of children with CH.

Keywords: children; congenital hypothyroidism (CH); levothyroxine (LT4); liquid thyroxine; tablets.

PubMed Disclaimer

References

    1. Bauer, AJ, Wassner, AJ. Thyroid hormone therapy in congenital hypothyroidism and pediatric hypothyroidism. Endocrine 2019;66:51–62. https://doi.org/10.1007/s12020-019-02024-6.
    1. O’Shaughnessy, KL, Thomas, SE, Spring, SR, Ford, JL, Ford, RL, Gilbert, ME. A transient window of hypothyroidism alters neural progenitor cells and results in abnormal brain development. Sci Rep 2019;15:4662. https://doi.org/10.1038/s41598-019-40249-7.
    1. Mengreli, C, Kassiou, K, Tsagaraki, S, Pantelakis, S. Neonatal screening for hypothyroidism in Greece. Eur J Pediatr 1981;137:185–7. https://doi.org/10.1007/BF00441314.
    1. Barry, Y, Bonaldi, C, Goulet, V, Coutant, R, Léger, J, Paty, AC, et al.. Increased incidence of congenital hypothyroidism in France from 1982 to 2012: a nationwide multicenter analysis. Ann Epidemiol 2016;26:100–5. https://doi.org/10.1016/j.annepidem.2015.11.005.
    1. McGrath, N, Hawkes, CP, McDonnell, CM, Cody, D, O’Connell, SM, Mayne, PD, et al.. Incidence of congenital hypothyroidism over 37 years in Ireland. Pediatrics 2018;142:e20181199. https://doi.org/10.1542/peds.2018-1199.

Publication types

LinkOut - more resources